* Evoke Pharma Inc EVOK.OQ reported a quarterly adjusted
loss
of 71 cents per share for the quarter ended in June. The lone
analyst forecast for the quarter was for a loss of 60 cents per
share.
* Revenue rose 95.2% to $462.00 thousand from a year ago;
analysts
expected $580.00 thousand.
* Evoke Pharma Inc's reported EPS for the quarter was a loss
of 71
cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Evoke Pharma Inc shares had fallen by 3.1% this
quarter and
lost 52.4% so far this year.
* The company reported a quarterly loss of $2.23 million.
* Wall Street's median 12-month price target for Evoke
Pharma Inc
is $78.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 10
at 09:03 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.60 -0.71 Missed
Mar. 31 2022 -0.48 -0.84 Missed
Dec. 31 2021 -0.96 -0.72 Beat
Sep. 30 2021 -0.84 -0.72 Beat